Table 2.
PPARD rs3734254 T>C |
PPARG rs10865710 C>G |
||||||||
---|---|---|---|---|---|---|---|---|---|
Genotype | Death/All | cHR (95% CI) | aHR** (95% CI) | Posterior aHR** (95% posterior limits) | Genotype | Death/All | cHR (95% CI) | aHR** (95% CI) | Posterior aHR** (95% posterior limits) |
Lung Cancer (N=611) | |||||||||
TT | 193/289 | 1.00 | 1.00 | 1.00 | CC | 186/286 | 1.00 | 1.00 | 1.00 |
TC | 112/168 | 1.02(0.81, 1.29) | 1.07(0.83, 1.37) | 1.08(0.84, 1.37) | CG | 130/192 | 1.11(0.88, 1.38) | 1.06(0.84, 1.34) | 1.06(0.85, 1.33) |
CC | 29/55 | 0.65(0.44, 0.96) | 0.63(0.42, 0.96) | 0.66(0.44, 0.98) | GG | 24/39 | 0.99(0.65, 1.51) | 1.11(0.71, 1.73) | 1.10(0.72, 1.68) |
Ptrend | 0.10 | 0.15 | 0.16 | Ptrend | 0.62 | 0.54 | 0.54 | ||
Recessive | 29/55 | 0.64(0.44, 0.94) | 0.61(0.41, 0.92) | 0.64(0.43, 0.94) | Recessive | 24/39 | 0.95(0.63, 1.44) | 1.07(0.70, 1.66) | 1.07(0.71, 1.62) |
Non-SCLC (N=536) | |||||||||
TT | 162/251 | 1.00 | 1.00 | 1.00 | CC | 162/254 | 1.00 | 1.00 | 1.00 |
TC | 97/150 | 1.04(0.81, 1.34) | 1.04(0.80, 1.36) | 1.05(0.80, 1.36) | CG | 105/162 | 1.05(0.82, 1.34) | 1.03(0.80, 1.33) | 1.03(0.80, 1.32) |
CC | 24/46 | 0.69(0.45, 1.06) | 0.69(0.44, 1.09) | 0.72(0.47, 1.10) | GG | 22/36 | 1.00(0.64, 1.55) | 1.14(0.71, 1.33) | 1.12(0.72, 1.76) |
Ptrend | 0.24 | 0.28 | 0.28 | Ptrend | 0.83 | 0.63 | 0.63 | ||
Recessive | 24/46 | 0.68(0.45, 1.03) | 0.68(0.44, 1.05) | 0.70(0.47, 1.06) | Recessive | 22/36 | 0.98(0.63, 1.51) | 1.12(0.71, 1.78) | 1.11(0.72, 1.72) |
SQC (N=95) | |||||||||
TT | 23/43 | 1.00 | 1.00 | 1.00 | CC | 18/35 | 1.00 | 1.00 | 1.00 |
TC | 16/27 | 1.22(0.65, 2.32) | 1.51(0.74, 3.05) | 1.40(0.75, 2.60) | CG | 22/37 | 1.27(0.68, 2.37) | 1.35(0.68, 2.67) | 1.26(0.69, 2.29) |
CC | 5/10 | 0.94(0.36, 2.46) | 0.91(0.30, 2.71) | 0.92(0.39, 2.13) | GG | 4/8 | 0.95(0.32, 2.80) | 1.21(0.35, 4.19) | 1.09(0.43, 2.75) |
Ptrend | 0.87 | 0.75 | 0.77 | Ptrend | 0.76 | 0.50 | 0.53 | ||
Recessive | 5/10 | 0.86(0.34, 2.20) | 0.74(0.26, 2.09) | 0.82(0.36, 1.86) | Recessive | 4/8 | 0.84(0.30, 2.34) | 1.01(0.31, 3.27) | 1.01(0.41, 2.47) |
ABC (N=297) | |||||||||
TT | 82/137 | 1.00 | 1.00 | 1.00 | CC | 83/141 | 1.00 | 1.00 | 1.00 |
TC | 54/87 | 1.13(0.80, 1.60) | 1.19(0.82, 1.73) | 1.18(0.83, 1.68) | CG | 57.89 | 1.22(0.87, 1.71) | 1.11(0.77, 1.58) | 1.09(0.78, 1.54) |
CC | 13/23 | 0.88(0.49, 1.58) | 0.99(0.51, 1.92) | 0.99(0.55, 1.79) | GG | 13/20 | 1.37(0.76, 2.46) | 1.24(0.65, 2.33) | 1.19(0.66, 2.12) |
Ptrend | 0.97 | 0.64 | 0.64 | Ptrend | 0.16 | 0.45 | 0.46 | ||
Recessive | 13/23 | 0.84(0.48, 1.49) | 0.90(0.48, 1.69) | 0.92(0.52, 1.63) | Recessive | 13/20 | 1.27(0.72, 2.24) | 1.18(0.64, 2.17) | 1.15(0.65, 2.02) |
LCC (N=115) | |||||||||
TT | 45/56 | 1.00 | 1.00 | 1.00 | CC | 50/64 | 1.00 | 1.00 | 1.00 |
TC | 23/31 | 0.82(0.50, 1.35) | 0.68(0.37, 1.25) | 0.75(0.44, 1.30) | CG | 19/27 | 0.74(0.44, 1.26) | 0.85(0.48, 1.48) | 0.87(0.52, 1.45) |
CC | 4/9 | 0.34(0.12, 0.95) | 0.32(0.09, 1.06) | 0.50(0.22, 1.15) | GG | 4/7 | 0.55(0.20, 1.52) | 0.87(0.26, 2.92) | 0.93(0.38, 2.29) |
Ptrend | 0.04 | 0.03 | 0.04 | Ptrend | 0.14 | 0.59 | 0.61 | ||
Recessive | 4/9 | 0.37(0.13, 1.01) | 0.36(0.11, 1.20) | 0.54(0.24, 1.23) | Recessive | 4/7 | 0.60(0.22, 1.65) | 0.94(0.28, 3.07) | 0.96(0.39, 2.36) |
SCLC (N=75) | |||||||||
TT | 31/38 | 1.00 | 1.00 | 1.00 | CC | 24/32 | 1.00 | 1.00 | 1.00 |
TC | 15/18 | 1.04(0.56, 1.92) | 1.22(0.61, 2.45) | 1.19(0.64, 2.22) | CG | 25/30 | 1.28(0.73, 2.25) | 1.03(0.54, 1.95) | 1.03(0.58, 1.84) |
CC | 5/9 | 0.43(0.17, 1.10) | 0.67 (0.20, 2.18) | 0.78(0.32, 1.91) | GG | 2/3 | 1.17(0.28, 4.93) | 0.80(0.17, 3.69) | 0.90(0.33, 2.46) |
Ptrend | 0.13 | 0.84 | 0.85 | Ptrend | 0.45 | 0.91 | 0.92 | ||
Recessive | 5/9 | 0.42(0.17, 1.07) | 0.63(0.20, 2.03) | 0.76(0.32, 1.84) | Recessive | 2/3 | 1.04(0.25, 4.27) | 0.79(0.18, 3.43) | 0.89(0.33, 2.39) |
Due to many 0 counts of PPARG rs1801282, the corresponding results were presented in supplementary tables.
Adjusted by age, gender, ethnicity, education level, smoking as packyears and tumor cell differentiation and morphology including squamous carcinoma, adenocarcinoma and large cell carcinoma and small cell carcinoma, if applicable.